Clinical trial
Open-label Trial of Leukine in Active Crohn's Disease
NCT00206700 · Genzyme, a Sanofi Company, Industry · Terminated
Key facts
| NCT number | NCT00206700 |
|---|---|
| Title | Open-label Trial of Leukine in Active Crohn's Disease |
| Official title | Open-label Trial of Leukine® (Sargramostim), A Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), in Active Crohn's Disease |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Crohn Disease |
| Intervention type | Drug |
| Interventions | Sargramostim (Leukine) |
| Enrollment | 378 |
| Start date | Feb 1, 2003 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Sep 21, 2005 |
| Last update posted | Dec 4, 2013 |
| Countries | Argentina, Australia, Brazil, Canada, New Zealand, Russia, Switzerland, Ukraine, United Kingdom, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: